Key result
Propionyl-L-carnitine plus exercise training did not improve peak walking time compared with exercise alone in patients with claudication.
Why the study?
The additional benefit of pharmacologic therapy with propionyl-L-carnitine combined with exercise training in patients with claudication secondary to peripheral artery disease had not been studied.
RCT (n=62)
Placebo-controlled
Randomized
Answers are grounded in this paper and cite their sources.
PURPOSE: Exercise training is established for the treatment of peripheral artery disease; however the additional benefit of pharmacologic therapy with exercise has not been studied. This trial tested the hypothesis that propionyl-L-carnitine (PLC), in combination with monitored home-based exercise training, would improve treadmill peak walking time (PWT) over exercise training alone. METHODS: Subjects with claudication were randomized to 6 months of therapy with PLC (2 g daily, n = 32) or matching placebo (n = 30). After supervised exercise instruction, all subjects performed exercise training sessions 3 times a week for 30 to 50 minutes/session and compliance was monitored by activity monitors and diary. Change in PWT was the primary outcome measure with other functional assessments predefined as secondary endpoints. RESULTS: After 6 months of treatment, patients randomized to training and placebo had an increase in PWT of 218 ± 367 seconds, while those randomized to training plus PLC had an increase of 266 ± 243 seconds, P = .258. Across the total study cohort, the dose of exercise training (total number of minutes of exercise of at least moderate intensity) was correlated with the change in PWT (r = 0.259, P = .048), suggesting that the monitored exercise was effective in improving walking performance in both treatment arms. CONCLUSIONS: In all subjects, the increase in PWT from baseline to month 6 was correlated with the amount of exercise training. However, although favoring PLC, the combination of exercise training and PLC did not result in a statistically significant benefit in peak treadmill performance or quality of life compared with exercise alone.
No takes yet. Share an insight, caveat, or question.
Hiatt et al. (2011) conducted an RCT in Claudication secondary to peripheral artery disease (n=62). Propionyl-L-carnitine (PLC) vs. Matching placebo was evaluated on Change in treadmill peak walking time (PWT) (p=.258). Propionyl-L-carnitine plus exercise training did not improve peak walking time compared with exercise alone in patients with claudication.
Synapse has enriched 10 related papers. Consider them for comparative context: